15. Net Loss per Share

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):


	Twelve Months Ended December 31, 2025
	Loss Allocation		Weighted Average Shares Outstanding	Loss Per Share, Basic and Diluted
Ordinary Shares	$	(133,446)	10,413,649	$	(12.81)
Company Series A Preferred Shares (1)	(20,496)		1,599	$	(12,818.01)
Net loss	$	(153,942)


	Period from September 19, 2024 (Inception) Through December 31, 2024
	Loss Allocation		Weighted Average Shares Outstanding	Loss Per Share, Basic and Diluted
Common Stock	$	(17,867)	767,580	$	(23.28)
Net loss	$	(17,867)

(1) The weighted-average number of shares of as-converted Series A Preferred Shares used in the loss allocation was 1,599,397 for the twelve months ended months ended December 31, 2025.

For the computation of basic net loss per share attributable to ordinary shareholders, the amount of weighted-average ordinary shares outstanding excludes all shares of unvested restricted stock and early-exercised stock options as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable. The potential ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have had an anti-dilutive effect were as follows:


	Twelve Months Ended December 31, 2025	Period from September 19, 2024 (Inception) Through December 31, 2024
Convertible preferred stock (as converted to common stock)	—	2,890,000
Outstanding unvested restricted stock units	741,454	—
Outstanding unvested restricted stock awards	82,129	246,753
Outstanding and issued common stock options	6,186,318	1,082,893
Total	7,009,901	4,219,646

About Earnings Per Share Disclosures

The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.

Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.

CRESCENT BIOPHARMA, INC. Earnings Per Share Disclosure

About Earnings Per Share Disclosures

Other Available Disclosures